 "Research lab image via Shutterstock.")
WuXi AppTec - the Chinese firm serving the pharmaceutical, biotechnology and medical device industries with its open-access R&D capability and technology platform - on April 15, 2016 acquired Crelux GmbH, a leading structure based drug discovery provider based in Munich (Germany). The addition of Crelux provides augmented scientific depth and complements existing capabilities within the WuXi structure-based drug discovery platform.
Crelux was founded in 2005 and has its laboratories at the Innovation Center for Biotechnology (IZB) in Martinsried. As a global leader in structure-based drug discovery, Crelux has been providing the drug discovery industry with highly individualised and efficient solutions to inform and accelerate their programmes for more than a decade. Crelux provides a number of customised services to support hit-finding, conformational analysis and lead optimisation, including protein production, biophysical assays, fragment screening, and X-ray crystallography.
The acquisition represents a further step in the growing European presence of WuXi AppTec and provides a solid foundation for WuXi to expand its integrated drug discovery services within Europe.
“The addition of Crelux will enable existing and prospective clients of both WuXi and Crelux to access enhanced hit finding, hit-to-lead, and lead optimization services with greater efficiency and scientific leadership. Crelux reflects our commitment to our European clients and adds strength to our existing comprehensive drug discovery capabilities within the WuXi Research Service Division,” said Dr Steve Yang, executive vice president and chief operating officer of WuXi AppTec.
